Search

Your search keyword '"Posthuma, Ward"' showing total 21 results
Start Over Author "Posthuma, Ward" Language english
21 results on '"Posthuma, Ward"'

1. Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study

Author

Saberi Hosnijeh, Fatemeh, van der Straten, Lina, Kater, Arnon P., van Oers, Marinus H.J., Posthuma, Ward F.M., Chamuleau, Martine E.D., Bellido, Mar, Doorduijn, Jeanette K., van Gelder, Michel, Hoogendoorn, Mels, de Boer, Fransien, te Raa, G. Doreen, Kerst, J. Martijn, Marijt, Erik W.A., Raymakers, Reinier A.P., Koene, Harry R., Schaafsma, Martijn R., Dobber, Johan A., Tonino, Sanne H., Kersting, Sabina S., Langerak, Anton W., and Levin, Mark-David

Published
2020
Full Text
View/download PDF

3. Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival

Author

De Groen, Ruben A.L., De Groot, Fleur A, De Haan, Lorraine M., van Wezel, Tom, Noordenbos, Troy, Boehringer, Stefan, Van Eijk, Ronald, Raghoo, Richard, Ruano, Dina, Sijs-Szabo, Aniko, te Boome, Liane, Terpstra, Valeska, Levenga, Henriette, Nicolae, Aline, Posthuma, Ward, Focke-Snieders, Isabelle, Hardi, Lizan, den Hartog, Wietske, Böhmer, Lara H., Van Den Berg, Anke, Mutseaers, Pim, Van Der Poel, Marjolein W.M., Abdul Hamid, Myrurgia, Woei-a-Jin, F.J. Sherida H., Janssens, Ann, Tousseyn, Thomas, Bovée, Judith, Veelken, Hendrik, Pals, Steven T, Diepstra, Arjan, Nijland, Marcel, Kersten, Marie José, Jansen, Patty M., Cleven, Arjen, and Vermaat, Joost S.P.

Published
2022
Full Text
View/download PDF

4. Feasibility and efficacy of addition of individualized dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

Author

Kater, Arnon P, van Oers, Marinus H J, van Norden, Yvette, van der Straten, Lina, Driessen, Julia, Posthuma, Ward F M, Schipperus, Martinus, Chamuleau, Martine E D, Nijland, Marcel, Doorduijn, Jeanette K, Van Gelder, Michel, Hoogendoorn, Mels, De Croon, Francien, Wittebol, Shulamiet, Kerst, J Martijn, Marijt, Erik W A, Raymakers, Reinier A P, Schaafsma, Martijn R, Dobber, Johan A, Kersting, Sabina A, Levin, Mark-David, and HOVON CLL study group

Subjects
Hematology
Abstract

Lenalidomide has been proven to be effective but with a distinct and difficult to manage toxicity profile in the context of chronic lymphocytic leukemia, potentially hampering combination treatment with this drug. We conducted a phase 1-2 study to evaluate the efficacy and safety of six cycles of chlorambucil (7 mg/m 2 daily), rituximab (375 mg/m 2 cycle 1 and 500 mg/m 2 cycles 2-6) and individually-dosed lenalidomide (escalated from 2.5 mg to 10 mg) (induction-I) in first-line treatment of patients with chronic lymphocytic leukemia unfit for treatment with fludarabine, cyclophosphamide and rituximab. This was followed by 6 months of 10 mg lenalidomide monotherapy (induction-II). Of 53 evaluable patients in phase 2 of the study, 47 (89%) completed induction-I and 36 (68%) completed induction-II. In an intention-to-treat analysis, the overall response rate was 83%. The median progression-free survival was 49 months, after a median follow-up time of 27 months. The 2-and 3-year progression-free survival rates were 58% and 54%, respectively. The corresponding rates for overall survival were 98% and 95%. No tumor lysis syndrome was observed, while tumor flair reaction occurred in five patients (9%, 1 grade 3). The most common hematologic toxicity was grade 3-4 neutropenia, which occurred in 73% of the patients. In conclusion, addition of lenalidomide to a chemotherapy backbone followed by a fixed duration of lenalidomide monotherapy resulted in high remission rates and progression-free survival rates, which seem comparable to those observed with novel drug combinations including novel CD20 monoclonal antibodies or kinase inhibitors. Although lenalidomide-specific toxicity remains a concern, an individualized dose-escalation schedule is feasible and results in an acceptable toxicity profile. EuraCT number: 2010-022294-34.

Published
2019

7. Hormone Replacement Therapy [with Reply]

Author

Duncan, Malcolm H., Stevenson, John C., Baum, Michael, Posthuma, Ward F. M., Westendorp, Rudi G. J., Vandenbroucke, Jan P., Air, Andrea, Lip, Gregory Y. H., and Beevers, D. Gareth

Published
1994

9. The BETER survivorship care initiative for Hodgkin lymphoma; Tailored survivorship care for late effects of treatment

Author

Dekker, Nicky, Van'T Veer, Mars B., Aleman, Berthe M.P., Van Leeuwen, Flora E., Raemaekers, John M.M., Schaapveld, Michael, Opstal-Van Winden, Annemieke, De Boer, Jan Paul, Sombroek, Cherita, Poortmans, Philip, Van Der Maazen, Richard, Lugtenburg, P. J.Elly, Janus, Cecile, Noordijk, Ed, Krol, A. D.G.Stijn, Daniels, Laurien, Zijlstra, Josée, Meijer, Otto, Petersen, Eefke, Buter, Denise, De Weijer, Roel, Roesink, Judith, Kluin-Nelemans, J. C.Hanneke, Van Imhoff, Gustaaf, De Vries, Floriske, Beijert, Max, Kersten, Marie José, Oldenburger, Foppe, Dieleman, Edith, Schouten, Harry, Borger, Jacques, Van De Voorde, Lien, Verschueren, Karijn, Schippers, Maaike, Verbeeten, Bernard, Ong, Francisca, Dorresteijn, Lucille, Schimmel, Erik, Bouma, Paul, Muller, Karin, Lybeert, Marnix, Dompeling, Ellen, Manenschijn, Annelies, Vos-Westerman, J. Hanneke, Van Kampen, Daphne, Dielwart, Michel, Posthuma, Ward, Böhmer, Lara, Te Boome, Liane, Visser, Hein, Epidemiology and Data Science, EMGO - Quality of care, Hematology, CCA - Imaging and biomarkers, CCA - Disease profiling, CCA - Imaging, Radiation Oncology, VU University medical center, and Oral and Maxillofacial Surgery / Oral Pathology

Subjects
humanities
Abstract

The Dutch BETER consortium has established a national care infrastructure for Hodgkin lymphoma survivors. 'BETER' [the Dutch word for 'better'] stands for Better care after Hodgkin lymphoma (HL): Evaluation of longterm Treatment Effects and screening Recommendations. The survivorship care focuses on longterm effects of HL treatment. Over 10,000 HL survivors who were treated in the period spanning 19652008 have been identified. As part of the survivorship care initiative, specific BETER outpatient clinics have been set up. A dedicated website, www.beternahodgkin.nl, provides HL survivors with relevant information. The stakeholders of the BETER survivorship care programme aim to achieve an improved healthy life expectancy for patients treated for HL.

Published
2016

14. Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib

Author

Sopper, Sieghart, Mustjoki, Satu, Loskog, Angelica, Gjertsen, Bjorn T, Greil, Richard, Lang, Alois, Linkesch, Werner, Thaler, Josef, Gedde-Dahl, Tobias, III, Hjorth-Jansen, Henrik, Majeed, Waleed, Lofti, Kourosh, Richter, Johan, Lehman, Sören, Stenke, Leif, Olsson-Strömberg, Ulla, Stentoft, Jesper, Posthuma, Ward, Smit, Willem, Vellenga, Edo, Verhoef, Gregor, Ferrant, Augustin, Van Droogenbroeck, Jan, Mark, Ute, Haenig, Jens, Jurjonas, Nidas, Gastl, Gunther, Giles, Frank, Hochhaus, Andreas, Ossenkoppele, Gert J., Porkka, Kimmo, and Wolf, Dominik

Published
2013
Full Text
View/download PDF

15. Integration of Mutational Signature Analysis with 3D Chromatin Data Unveils Differential AID-Related Mutagenesis in Indolent Lymphomas.

Author

Sepulveda-Yanez, Julieta H., Alvarez-Saravia, Diego, Fernandez-Goycoolea, Jose, Aldridge, Jacqueline, van Bergen, Cornelis A. M., Posthuma, Ward, Uribe-Paredes, Roberto, Veelken, Hendrik, and Navarrete, Marcelo A.

Subjects
DNA repair, LYMPHOMAS, MUTAGENESIS, DNA analysis, CHRONIC lymphocytic leukemia, FOLLICULAR lymphoma
Abstract

Activation-induced deaminase (AID) is required for somatic hypermutation in immunoglobulin genes, but also induces off-target mutations. Follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL), the most frequent types of indolent B-cell tumors, are exposed to AID activity during lymphomagenesis. We designed a workflow integrating de novo mutational signatures extraction and fitting of COSMIC (Catalogue Of Somatic Mutations In Cancer) signatures, with tridimensional chromatin conformation data (Hi-C). We applied the workflow to exome sequencing data from lymphoma samples. In 33 FL and 30 CLL samples, 42% and 34% of the contextual mutations could be traced to a known AID motif. We demonstrate that both CLL and FL share mutational processes dominated by spontaneous deamination, failures in DNA repair, and AID activity. The processes had equiproportional distribution across active and nonactive chromatin compartments in CLL. In contrast, canonical AID activity and failures in DNA repair pathways in FL were significantly higher within the active chromatin compartment. Analysis of DNA repair genes revealed a higher prevalence of base excision repair gene mutations (p = 0.02) in FL than CLL. These data indicate that AID activity drives the genetic landscapes of FL and CLL. However, the final result of AID-induced mutagenesis differs between these lymphomas depending on chromatin compartmentalization and mutations in DNA repair pathways. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

20. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased?

Author

Posthuma, Ward F.M., Westendorp, Rudi G.J., and Vandenbroucke, Jan P.

Subjects
*HORMONE therapy for menopause, *DISEASES in women
Abstract

Examines the cardioprotective effect of hormone replacement therapy in postmenopausal women. Comparison on relative risks between cardiovascular disease and cancer; Benefits of hormone replacement therapy; Implications on the administration of oestrogen replacement therapy.

Published
1994

21. Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.

Author

Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, Van Gelder M, Hoogendoorn M, De Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting S, and Levin MD

Subjects
Adolescent, Adult, Chlorambucil administration & dosage, Disease-Free Survival, Feasibility Studies, Female, Humans, Lenalidomide administration & dosage, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Male, Middle Aged, Rituximab administration & dosage, Survival Rate, Vidarabine administration & dosage, Vidarabine analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell mortality
Abstract

Lenalidomide has been proven to be effective but with a distinct and difficult to manage toxicity profile in the context of chronic lymphocytic leukemia, potentially hampering combination treatment with this drug. We conducted a phase 1-2 study to evaluate the efficacy and safety of six cycles of chlorambucil (7 mg/m 2 daily), rituximab (375 mg/m 2 cycle 1 and 500 mg/m 2 cycles 2-6) and individually-dosed lenalidomide (escalated from 2.5 mg to 10 mg) (induction-I) in first-line treatment of patients with chronic lymphocytic leukemia unfit for treatment with fludarabine, cyclophosphamide and rituximab. This was followed by 6 months of 10 mg lenalidomide monotherapy (induction-II). Of 53 evaluable patients in phase 2 of the study, 47 (89%) completed induction-I and 36 (68%) completed induction-II. In an intention-to-treat analysis, the overall response rate was 83%. The median progression-free survival was 49 months, after a median follow-up time of 27 months. The 2- and 3-year progression-free survival rates were 58% and 54%, respectively. The corresponding rates for overall survival were 98% and 95%. No tumor lysis syndrome was observed, while tumor flair reaction occurred in five patients (9%, 1 grade 3). The most common hematologic toxicity was grade 3-4 neutropenia, which occurred in 73% of the patients. In conclusion, addition of lenalidomide to a chemotherapy backbone followed by a fixed duration of lenalidomide monotherapy resulted in high remission rates and progression-free survival rates, which seem comparable to those observed with novel drug combinations including novel CD20 monoclonal antibodies or kinase inhibitors. Although lenalidomide-specific toxicity remains a concern, an individualized dose-escalation schedule is feasible and results in an acceptable toxicity profile. EuraCT number: 2010-022294-34 ., (Copyright© 2019 Ferrata Storti Foundation.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results